CanalLotus Biotech — News & Drug Development https://www.canallotus.com/ Comparator drug supply, clinical trial materials, drug import and export, and drug development calculators. en Tue, 10 Nov 2026 00:00:00 +0800 CanalLotus static feed FDA Approves Sunharbo (asundexian) in Combination with Antiplatelet Therapy for Secondary Stroke Prevention https://www.canallotus.com/article/1216.html https://www.canallotus.com/article/1216.html Tue, 10 Nov 2026 00:00:00 +0800 Company business introduction https://www.canallotus.com/article/1215.html https://www.canallotus.com/article/1215.html Fri, 06 Nov 2026 00:00:00 +0800 FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis https://www.canallotus.com/article/1214.html https://www.canallotus.com/article/1214.html Tue, 03 Nov 2026 00:00:00 +0800 FDA Approves Lucamzi (ranibizumab-blrz), a Biosimilar to Lucentis https://www.canallotus.com/article/1213.html https://www.canallotus.com/article/1213.html Mon, 02 Nov 2026 00:00:00 +0800 FDA Approves Hibsago (bepirovirsen) for the Treatment of Chronic Hepatitis B https://www.canallotus.com/article/1212.html https://www.canallotus.com/article/1212.html Fri, 30 Oct 2026 00:00:00 +0800 FDA Approves Brytly (apraclonidine) Ophthalmic Solution for Relief of Eye Redness https://www.canallotus.com/article/1211.html https://www.canallotus.com/article/1211.html Thu, 29 Oct 2026 00:00:00 +0800 FDA Approves Hovilpri (pritelivir) for the Treatment of Mucocutaneous Herpes Simplex Virus (HSV) Lesions https://www.canallotus.com/article/1210.html https://www.canallotus.com/article/1210.html Tue, 27 Oct 2026 00:00:00 +0800 FDA Approves Weltruza (olanzapine) Once-Monthly Subcutaneous Injection for the Treatment of Adults with Schizophrenia https://www.canallotus.com/article/1209.html https://www.canallotus.com/article/1209.html Mon, 26 Oct 2026 00:00:00 +0800 FDA Approves Emcitate (tiratricol) for the Treatment of Patients with MCT8 Deficiency https://www.canallotus.com/article/1208.html https://www.canallotus.com/article/1208.html Fri, 23 Oct 2026 00:00:00 +0800 FDA Approves Juvmo (tavapadon) for the Treatment of Parkinson's Disease https://www.canallotus.com/article/1207.html https://www.canallotus.com/article/1207.html Thu, 22 Oct 2026 00:00:00 +0800 FDA Approves Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva https://www.canallotus.com/article/1206.html https://www.canallotus.com/article/1206.html Wed, 21 Oct 2026 00:00:00 +0800 FDA Approves Degevma (denosumab-adet), a Biosimilar to Xgeva https://www.canallotus.com/article/1205.html https://www.canallotus.com/article/1205.html Tue, 20 Oct 2026 00:00:00 +0800 FDA Approves Lamlique (lamotrigine) Oral Suspension for Seizures and Bipolar Disorder https://www.canallotus.com/article/1204.html https://www.canallotus.com/article/1204.html Fri, 16 Oct 2026 00:00:00 +0800 FDA Approves Onswik (insulin efsitora alfa-gobe) Once-Weekly Basal Insulin for Adults with Type 2 Diabetes https://www.canallotus.com/article/1203.html https://www.canallotus.com/article/1203.html Thu, 15 Oct 2026 00:00:00 +0800 FDA Approves Lyrfigtu (lirafugratinib) for the Treatment of Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement https://www.canallotus.com/article/1201.html https://www.canallotus.com/article/1201.html Wed, 14 Oct 2026 00:00:00 +0800 FDA Approves Bravnetsa (lutetium Lu 177 dotatate) as a Therapeutic Equivalent to Lutathera for the Treatment of Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors in Adults https://www.canallotus.com/article/1200.html https://www.canallotus.com/article/1200.html Tue, 13 Oct 2026 00:00:00 +0800 FDA Approves Fayuvi (rebisufligene etisparvovec-hopf) Gene Therapy for the Treatment for Sanfilippo Syndrome Type A (MPS IIIA) https://www.canallotus.com/article/1199.html https://www.canallotus.com/article/1199.html Tue, 22 Sep 2026 00:00:00 +0800 FDA Approves Bexlutry (lutetium Lu 177 dotatate) for Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors https://www.canallotus.com/article/1198.html https://www.canallotus.com/article/1198.html Mon, 21 Sep 2026 00:00:00 +0800 FDA Approves Pixclara (floretyrosine F 18) FET-PET Imaging Agent for Glioma https://www.canallotus.com/article/1197.html https://www.canallotus.com/article/1197.html Sun, 20 Sep 2026 00:00:00 +0800 FDA Approves Isembyld (apitegromab-mstn) Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) https://www.canallotus.com/article/1196.html https://www.canallotus.com/article/1196.html Mon, 14 Sep 2026 00:00:00 +0800 FDA Grants Accelerated Approval to Etcamah (camizestrant) in Combination with a CDK4/6 Inhibitor for the Treatment of Advanced HR-Positive Breast Cancer https://www.canallotus.com/article/1195.html https://www.canallotus.com/article/1195.html Tue, 08 Sep 2026 00:00:00 +0800 FDA Approves Zanvastro (zilganersen) for the Treatment of Alexander Disease https://www.canallotus.com/article/1194.html https://www.canallotus.com/article/1194.html Mon, 07 Sep 2026 00:00:00 +0800 FDA Approves Mimrylo (rusfertide) for the Treatment of Polycythemia Vera https://www.canallotus.com/article/1193.html https://www.canallotus.com/article/1193.html Fri, 04 Sep 2026 00:00:00 +0800 FDA Approves Bixlenvo (bictegravir and lenacapavir) for the Treatment of HIV in Adults Who Are Virologically Suppressed https://www.canallotus.com/article/1192.html https://www.canallotus.com/article/1192.html Thu, 03 Sep 2026 00:00:00 +0800 FDA Approves Lisraya (brepocitinib) for the Treatment of Adults with Dermatomyositis https://www.canallotus.com/article/1191.html https://www.canallotus.com/article/1191.html Fri, 28 Aug 2026 00:00:00 +0800 FDA Approves Rasonque (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer https://www.canallotus.com/article/1190.html https://www.canallotus.com/article/1190.html Thu, 27 Aug 2026 00:00:00 +0800 FDA Approves Pasatru (garetosmab-grts) for the Treatment of Fibrodysplasia Ossificans Progressiva https://www.canallotus.com/article/1189.html https://www.canallotus.com/article/1189.html Fri, 21 Aug 2026 00:00:00 +0800 FDA Grants Accelerated Approval for Genglycos (pariglasgene brecaparvovec-opnr) Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia https://www.canallotus.com/article/1188.html https://www.canallotus.com/article/1188.html Thu, 20 Aug 2026 00:00:00 +0800 FDA Grants Accelerated Approval to Zenbexus (iberdomide) in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for the Treatment of Multiple Myeloma https://www.canallotus.com/article/1187.html https://www.canallotus.com/article/1187.html Wed, 19 Aug 2026 00:00:00 +0800 FDA Approves Tauklarify (florquinitau F 18 injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease https://www.canallotus.com/article/1186.html https://www.canallotus.com/article/1186.html Tue, 18 Aug 2026 00:00:00 +0800 FDA Grants Accelerated Approval to Tudriqev (vusolimogene oderparepvec-wtpg) in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma https://www.canallotus.com/article/1185.html https://www.canallotus.com/article/1185.html Mon, 17 Aug 2026 00:00:00 +0800 FDA Approves Orzeyful (oveporexton) to Treat the Underlying Cause of Narcolepsy Type 1 https://www.canallotus.com/article/1184.html https://www.canallotus.com/article/1184.html Fri, 14 Aug 2026 00:00:00 +0800 FDA Approves mFLUSIVA (influenza vaccine, mRNA) for the Prevention of Seasonal Influenza https://www.canallotus.com/article/1183.html https://www.canallotus.com/article/1183.html Thu, 13 Aug 2026 00:00:00 +0800 FDA Approves Gwyn Lo (norelgestromin and ethinyl estradiol) Once-Weekly Contraceptive Patch https://www.canallotus.com/article/1182.html https://www.canallotus.com/article/1182.html Wed, 12 Aug 2026 00:00:00 +0800 FDA Approves Lytenava (bevacizumab-vikg) for the Treatment of Wet Age-Related Macular Degeneration https://www.canallotus.com/article/1181.html https://www.canallotus.com/article/1181.html Tue, 11 Aug 2026 00:00:00 +0800 FDA Approves Simtriyo (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) https://www.canallotus.com/article/1180.html https://www.canallotus.com/article/1180.html Fri, 07 Aug 2026 00:00:00 +0800 FDA Approves Tylenol with Naproxen (acetaminophen and naproxen sodium) for Over-the-Counter Treatment of Pain https://www.canallotus.com/article/1179.html https://www.canallotus.com/article/1179.html Wed, 05 Aug 2026 00:00:00 +0800 FDA Approves Garzulys (insulin aspart-fsan), a Biosimilar to NovoLog https://www.canallotus.com/article/1178.html https://www.canallotus.com/article/1178.html Tue, 04 Aug 2026 00:00:00 +0800 FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer https://www.canallotus.com/article/1177.html https://www.canallotus.com/article/1177.html Thu, 30 Jul 2026 00:00:00 +0800 FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia https://www.canallotus.com/article/1176.html https://www.canallotus.com/article/1176.html Mon, 27 Jul 2026 00:00:00 +0800 FDA Approves Revtorpyk (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer https://www.canallotus.com/article/1175.html https://www.canallotus.com/article/1175.html Thu, 23 Jul 2026 00:00:00 +0800 FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma https://www.canallotus.com/article/1174.html https://www.canallotus.com/article/1174.html Wed, 22 Jul 2026 00:00:00 +0800 FDA Grants Accelerated Approval for Trutakna (atacicept-vymj) for Adult Patients with Primary IgA Nephropathy https://www.canallotus.com/article/1173.html https://www.canallotus.com/article/1173.html Tue, 21 Jul 2026 00:00:00 +0800 FDA Approves Tregzi (Orca-T) as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies https://www.canallotus.com/article/1172.html https://www.canallotus.com/article/1172.html Fri, 17 Jul 2026 00:00:00 +0800 FDA Approves Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease https://www.canallotus.com/article/1171.html https://www.canallotus.com/article/1171.html Mon, 29 Jun 2026 00:00:00 +0800 FDA Approves Utebzi (tebipenem pivoxil) for Adults with Complicated Urinary Tract Infections https://www.canallotus.com/article/1170.html https://www.canallotus.com/article/1170.html Wed, 24 Jun 2026 00:00:00 +0800 FDA Approves Xocova (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure https://www.canallotus.com/article/1169.html https://www.canallotus.com/article/1169.html Fri, 05 Jun 2026 00:00:00 +0800 FDA Approves Zaynich (cefepime and zidebactam) for the Treatment of Complicated Urinary Tract Infections https://www.canallotus.com/article/1168.html https://www.canallotus.com/article/1168.html Thu, 04 Jun 2026 00:00:00 +0800 FDA Approves Decnupaz (pivekimab sunirine-pvzy) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm https://www.canallotus.com/article/1167.html https://www.canallotus.com/article/1167.html Wed, 03 Jun 2026 00:00:00 +0800 FDA Grants Accelerated Approval to Hepcludex (bulevirtide-gmod) Treatment for Chronic Hepatitis Delta Virus (HDV) https://www.canallotus.com/article/1166.html https://www.canallotus.com/article/1166.html Tue, 02 Jun 2026 00:00:00 +0800